share_log

东方生物(688298.SH):7月未通过集中竞价交易方式实施股份回购

Zhejiang Orient Gene Biotech (688298.SH): Did not pass the centralized bidding method to implement share repurchase in July.

Gelonghui Finance ·  Aug 1 05:31

On July 2024, Zhejiang Orient Gene Biotech (688298.SH) announced that it did not repurchase shares through centralized bidding trading. As of July 31st, 2024, the company repurchased a cumulative total of 8.3327 million shares through the Shanghai Stock Exchange's centralized bidding trading system, accounting for 4.13% of the company's total share capital of 201.6 million shares. The minimum price for repurchasing shares is 27.83 yuan/share, the highest price is 34.50 yuan/share, and the total amount paid for the repurchase is 0.275 billion yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment